Proskauer

Proskauer Advises Nexus Pharmaceuticals on Sale to PAI Pharma

November 18, 2026

LOS ANGELES and NEW YORK, November 18, 2026 – Proskauer advised Nexus Pharmaceuticals, LLC ("Nexus") on its sale to PAI Pharma ("PAI"), a leading U.S. developer, manufacturer, and marketer of oral liquid medicines and Ready-To-Use sterile injectables and hospital-focused products, and a portfolio company of Olympus Partners.

Nexus is a pharmaceutical company specializing in the development and commercialization of injectable medicines used in critical care, oncology, and other hospital settings. The acquisition will help PAI build a broader portfolio of essential medicines and expand its presence in the hospital and sterile injectable markets, with Nexus adding more than 20 hospital injectable products.

The Proskauer team was led by partners Christopher Ahn and Anya Hodes (Private Equity Transactions/M&A) and partner Muhyung (Aaron) Lee (Tax) and included associates Benjamin Childress and Donya Aframian (Private Equity Transactions/M&A); partner Devin Cohen and associate Lara Feder (Health Care); associate Ziyu (Jessie) Lin (Tax); partner Nick LaSpina and associate David Deutsch (Compensation & Benefits); partner Mark Rutter (Real Assets); partner Aliza Cinamon (Environmental); partners John Ingrassia, Eric Johnson and Mary Wilks (Antitrust & Foreign Investment); partner Nathan Lander (Insurance); partner Erik Milch (Patent Law); and senior counsel Judith Rubin (Privacy & Cybersecurity).

About Proskauer

Proskauer is an elite global law firm with more than 900 lawyers in key financial centers in the United States, Europe, South America, and Asia. Our clients include many of the world's leading businesses, including asset managers, banks, listed corporations, and private companies. We have deep expertise in several of the fastest-growing and dynamic segments of the market, including sports, technology, life sciences, and health care. We represent hundreds of asset managers across a wide spectrum of sectors and strategies, including private equity, private credit, hedge, real assets, secondaries, and capital solutions.

Our premier M&A practice is distinguished by the combination of our transactional strength and deep sector knowledge. We are a destination firm for large-cap and middle-market deals with extensive expertise in the structural, cultural, and procedural issues that are often at the center of complex, cross-border transactions. From London to New York, Paris to Los Angeles and across the globe, organizations turn to our lawyers for their most significant and transformative transactions. Our multidisciplinary team offers actionable insights, sophisticated strategies, and creative solutions that drive commercial success for our clients.

Related Professionals

- **Aliza R. Cinamon**
  Partner
- **Anya Hodes**
  Partner
- **Benjamin G. Childress**
  Associate
- **Christopher D. Ahn**
  Partner
- **David E. Deutsch**
  Associate
- **Devin Cohen**
  Partner
- **Donya Aframian**
  Associate

- **Eric S. Johnson**
  Partner
- **Erik Milch**
  Partner
- **John R. Ingrassia**
  Partner
- **Judith Rubin**
  Senior Counsel
- **Lara H. Feder**
  Law Clerk
- **Mark Rutter**
  Partner
- **Mary Wilks**
  Partner
- **Muhyung (Aaron) Lee**
  Partner
- **Nathan R. Lander**
  Partner
- **Nicholas P. LaSpina**
  Partner
- **Ziyu (Jessie) Lin**
  Associate